Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
2021 Novartis full year guidance
Barring unforeseen events; growth vs. PY in cc
Group | full year guidance¹
vs. PY (cc)
Group sales expected to grow low to mid single digit
■ IM Division expected to grow mid single digit
☐
■ Sandoz expected to decline low to mid single digit
Group core operating income expected to grow mid single digit, ahead of sales
IM Division expected to grow mid to high single digit, ahead of sales
Sandoz expected to decline low to mid teens
1. Key assumptions:
Our guidance assumes that we see a continuation of the return to normal global healthcare systems including prescription dynamics, particularly oncology, in H2 2021
In addition, we assume that no GilenyaⓇ and no Sandostatin® LAR generics enter in 2021 in the US
35 Investor Relations | Q2 2021 Results
1 NOVARTIS | Reimagining MedicineView entire presentation